Actively Recruiting
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-01-29
49
Participants Needed
10
Research Sites
199 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
G
Genentech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
CONDITIONS
Official Title
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at time of signing informed consent.
- ECOG performance status of 0 or 1.
- HER2-positive esophageal, gastroesophageal junction, or gastric adenocarcinoma confirmed by biopsy or resection specimen.
- Complete surgical removal of the primary tumor must be achievable.
- Adequate organ function as defined by specific blood counts, kidney, liver, and coagulation measures.
- Male participants must agree to use contraception during treatment and for at least 230 days after last dose.
- Female participants must not be pregnant or breastfeeding and must meet specific contraception or fertility status requirements.
You will not qualify if you...
- Presence of metastatic or recurrent disease.
- Prior treatment for esophagogastric cancer.
- Previous therapy with anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-HER2 agents.
- Left ventricular ejection fraction below 50% within 1 month before screening.
- Participation in another investigational study within 4 weeks prior to treatment.
- Diagnosis of immunodeficiency or recent use of systemic immunosuppressive therapy.
- Known active tuberculosis.
- Allergy to pembrolizumab or its components.
- Diagnosis or treatment for another cancer in the past 3 years (except non-melanoma skin cancer).
- Known active central nervous system metastases or carcinomatous meningitis.
- Active non-infectious pneumonitis.
- Active infection requiring systemic therapy.
- Conditions or treatments that may interfere with study participation or results.
- Psychiatric or substance abuse disorders interfering with study cooperation.
- Pregnant, breastfeeding, or planning to conceive or father children during the study.
- Positive pregnancy test for women of childbearing potential within 72 hours prior to allocation.
- History of allogeneic tissue or solid organ transplant.
- Active or prior autoimmune or inflammatory disorders within 3 years, with some exceptions.
- Known HIV infection.
- Active hepatitis B or C infection.
- Receipt of live vaccine within 30 days before starting study therapy.
- Unwilling or unable to give consent or comply with the study protocol.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Massachusetts General Hospital (Data Collection Only)
Boston, Massachusetts, United States, 02114
Actively Recruiting
2
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
3
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
4
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
5
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
Commack, New York, United States, 11725
Actively Recruiting
6
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
7
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
8
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
9
University of Pennsylvania (Data Collection Only)
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
10
MD Anderson Cancer Center (Data Collection Only)
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
Y
Yelena Janjigian, MD
CONTACT
S
Samuel Cytryn, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here